department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Inveltys · pharmadog

pharmadog
drugs
Inveltys

drug

patient view →

loteprednol etabonate

Marketedupdated 2mo ago

by $ALC ALCON INC

Approved

community read0 votes

all catalysts(1)

approval · 1

LOTEPREDNOL ETABONATE AND TOBRAMYCIN (LOTEPREDNOL ETABONATE) — FDA approval

loteprednol etabonate

News(0)

no news has mentioned this drug yet

brand

Inveltys

generic

loteprednol etabonate

indication

Ocular Inflammation

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 14, 2026

7 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (32)

Dec 23, 2036formulationUS 10596107
Jan 26, 2036formulationUS 11534395
May 3, 2033formulationUS 10058511
May 3, 2033formulationUS 10058511
May 3, 2033formulationUS 10646436
May 3, 2033formulationUS 10646437
May 3, 2033formulationUS 10688045
May 3, 2033formulationUS 10688045
May 3, 2033method-of-use (U-2985)US 10857096
May 3, 2033method-of-use (U-3011)US 10864219
May 3, 2033method-of-use (U-2985)US 10940108
May 3, 2033method-of-use (U-2985)US 10945948
May 3, 2033method-of-use (U-3117)US 10993908
May 3, 2033method-of-use (U-2985)US 11219596
May 3, 2033method-of-use (U-3279)US 11219597
May 3, 2033method-of-use (U-2985)US 11596599
May 3, 2033formulationUS 11642317
May 3, 2033formulationUS 11642317
May 3, 2033formulationUS 11872318
May 3, 2033formulationUS 11872318
May 3, 2033formulationUS 12115246
May 3, 2033formulationUS 12115246
May 3, 2033formulationUS 9056057
May 3, 2033formulationUS 9056057
May 3, 2033formulationUS 9393213
May 3, 2033formulationUS 9393213
May 3, 2033method-of-use (U-2491)US 9532955
May 3, 2033method-of-use (U-2491)US 9532955
May 3, 2033method-of-use (U-2492)US 9737491
May 3, 2033method-of-use (U-2492)US 9737491
May 3, 2033formulationUS 9827191
May 3, 2033formulationUS 9827191

FDA exclusivities (1)

Jul 14, 2026CGTCGT7d

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 6

drugLotemax SM4 co-mentions · 1 sources
drugLOTEPREDNOL ETABONATE AND TOBRAMYCIN4 co-mentions · 1 sources
tagApproval4 co-mentions · 1 sources
drugtobramycin2 co-mentions · 1 sources
drugTobi Podhaler2 co-mentions · 1 sources
drugTobrabact2 co-mentions · 1 sources

Trials studying loteprednol etabonate

phase4Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Periodcompletedn=77
phase4Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejectioncompletedn=70